国药现代：全资孙公司获盐酸米那普仑原料药上市申请批准

Core Viewpoint - The approval of the active pharmaceutical ingredient, Mianaprine Hydrochloride, by the National Medical Products Administration is a significant milestone for the company, enhancing its integrated supply chain capabilities while facing sales uncertainties due to various factors [1] Group 1: Regulatory Approval - The company's wholly-owned subsidiary, China National Pharmaceutical Group Jiangsu Weichida, received the approval notice for the listing application of Mianaprine Hydrochloride [1] - The approval is crucial for the treatment of severe depression, with a global consumption of 3,639.95 kg in 2023 [1] Group 2: Research and Development - The application for the active pharmaceutical ingredient was submitted in October 2024 and passed the review in February 2026 [1] - The total R&D investment for this project amounted to approximately 7.1823 million yuan [1] Group 3: Market Implications - The approval supports the company's efforts to advance its integrated supply chain [1] - However, sales of the product may be influenced by multiple factors, leading to uncertainties in market performance [1]